Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 22 April, 2024|Author: Getaka | Social: X Twitter Profile
Stock Ticker - BSE: 524804 | NSE: AUROPHARMA

Fundamental Analysis of Aurobindo Pharma Ltd

Basic Stock Data

Last Updated: April 20, 2024, 7:48 am

Market Cap 63,694 Cr.
Current Price 1,087
High / Low1,177/581
Stock P/E22.7
Book Value 481
Dividend Yield0.41 %
ROCE9.20 %
ROE7.47 %
Face Value 1.00

Data Source: screener.in

Competitors of Aurobindo Pharma Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
SMS Lifesciences India Ltd 219 Cr. 725790/46479.1 5530.21 %7.92 %6.12 % 10.0
Lupin Ltd 70,530 Cr. 1,5481,704/68039.4 2910.26 %5.73 %3.33 % 2.00
Unichem Laboratories Ltd 4,072 Cr. 578607/365 3420.00 %4.58 %7.05 % 2.00
Ambalal Sarabhai Enterprises Ltd 363 Cr. 47.470.0/20.9126 16.60.00 %11.1 %8.99 % 10.0
Chandra Bhagat Pharma Ltd 86.6 Cr. 115160/80.074.1 37.30.00 %7.13 %3.36 % 10.0
Industry Average15,054.12 Cr602.6863.72247.980.09%7.29%5.77%6.80

Quarterly Result

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Sales6,3656,0025,7025,9426,0025,8096,2365,7396,4076,4736,8517,2197,352
Expenses5,0114,7354,5024,7664,9934,8395,3034,9505,4535,4775,7025,8465,753
Operating Profit1,3541,2661,2001,1761,0099709337909549961,1491,3731,599
OPM %21%21%21%20%17%17%15%14%15%15%17%19%22%
Other Income2,9477911097100-11441579313547188163
Interest1918131016915254556576876
Depreciation277266280294299254280298321346327418423
Profit before tax4,0051,0611,0189687945946795236807308121,0761,262
Tax %26%24%24%28%24%3%23%22%28%31%30%30%26%
Net Profit2,948801770697604576520410491506570752940
EPS in Rs50.3113.6813.1411.9010.329.848.886.998.388.649.7412.9215.98

Last Updated: April 10, 2024, 6:15 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: April 6, 2024, 1:44 pm

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales4,6155,8428,08912,10313,77214,91016,46319,56423,09924,77523,45524,85527,895
Expenses4,0504,9655,9519,52410,57911,46912,69115,61218,24919,49719,06021,14822,778
Operating Profit5658772,1372,5793,1933,4413,7723,9524,8495,2784,3963,7075,117
OPM %12%15%26%21%23%23%23%20%21%21%19%15%18%
Other Income-300121881200115105701663,195152291532
Interest27726731016025767782633057449140256
Depreciation2012493133333924285586689671,0551,1271,2451,513
Profit before tax-2133741,5332,1682,7443,0613,2413,0913,7437,3443,3732,6123,880
Tax %42%22%24%28%26%25%25%24%24%27%22%26%
Net Profit-1242911,1691,5712,0242,3012,4232,3642,8445,3342,6471,9282,768
EPS in Rs-2.125.0520.1226.9834.6139.2941.3640.3648.5691.0545.2032.9047.28
Dividend Payout %-24%15%7%8%7%6%6%6%6%4%20%23%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2012-20132013-20142014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-2023
YoY Net Profit Growth (%)334.68%301.72%34.39%28.84%13.69%5.30%-2.43%20.30%87.55%-50.37%-27.16%
Change in YoY Net Profit Growth (%)0.00%-32.96%-267.33%-5.55%-15.15%-8.38%-7.74%22.74%67.25%-137.93%23.21%

Growth

Compounded Sales Growth
10 Years:16%
5 Years:9%
3 Years:2%
TTM:15%
Compounded Profit Growth
10 Years:21%
5 Years:-5%
3 Years:-12%
TTM:30%
Stock Price CAGR
10 Years:15%
5 Years:7%
3 Years:5%
1 Year:92%
Return on Equity
10 Years:18%
5 Years:14%
3 Years:12%
Last Year:7%

Last Updated: April 16, 2024, 9:10 pm

Balance Sheet

Last Updated: April 22, 2024, 12:19 am

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital29292929595959595959595959
Reserves2,3112,5773,7215,1277,2299,31311,62213,83216,76621,87124,51726,78128,130
Borrowings3,0963,4353,7694,4515,0413,3644,7706,9675,8265,3392,8515,2866,649
Other Liabilities7981,2321,9703,3033,5683,4644,4925,4146,1136,1476,2117,3799,086
Total Liabilities6,2347,2739,49012,91015,89616,20020,94226,27128,76533,41633,63839,50543,924
Fixed Assets2,1952,6392,7223,7064,1804,8346,5218,4759,3969,37410,53211,02411,704
CWIP6452193104208481,4581,5831,6681,9863,0623,7475,3905,798
Investments39222020123246312360555591997543435
Other Assets3,3554,3936,4398,76510,7459,66212,52715,76816,82720,39018,36222,54925,986
Total Assets6,2347,2739,49012,91015,89616,20020,94226,27128,76533,41633,63839,50543,924

Reserves and Borrowings Chart

Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Cash from Operating Activity 3262756461,2371,4203,2791,9551,6514,3813,3295,0162,387
Cash from Investing Activity -563-246-819-1,017-1,446-1,787-1,927-2,904-1,563597-3,211-3,978
Cash from Financing Activity 11910811893365-1,9158641,919-1,947-1,365-2,9691,814
Net Cash Flow-118137-55313340-4248926668712,561-1,164223

Free Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Free Cash Flow562.00874.00-1.00-2.00-2.000.00-1.00-3.00-1.000.002.00-2.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days9810011910712268686468526266
Inventory Days224235240239240246317304289333272275
Days Payable961181371361461221281079710397125
Cash Conversion Cycle226217222210217191257260260282237216
Working Capital Days148171162126141122139148120124120120
ROCE %8%11%27%27%27%25%23%18%19%18%13%9%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Promoters51.94%51.83%51.83%51.83%51.83%51.83%51.84%51.84%51.84%51.84%51.84%51.84%
FIIs24.37%23.70%21.71%21.37%20.83%20.71%21.41%22.31%23.03%24.12%22.45%20.72%
DIIs13.24%14.66%15.52%16.49%17.47%17.30%16.56%14.90%15.09%15.73%18.29%20.60%
Public10.45%9.80%10.93%10.31%9.86%10.15%10.20%10.96%10.06%8.31%7.43%6.85%
No. of Shareholders2,32,6342,43,3153,29,9403,41,5683,38,6393,59,6843,58,4593,69,8283,43,6172,93,2142,59,6382,41,944

Shareholding Pattern Chart

No. of Shareholders

Aurobindo Pharma Ltd Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)
HDFC Mid-Cap Opportunities Fund - Regular Plan120228222.341383.11
HDFC Hybrid Equity Fund - Regular Plan40000002.05460.16
HDFC Balanced Advantage Fund - Regular Plan28358120.42326.23
SBI Arbitrage Opportunities Fund25102001.08288.77
ICICI Prudential Value Discovery Fund23081480.67265.53
HDFC Top 100 Fund - Regular Plan22768030.85261.92
ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund18992756.13218.49
HDFC Arbitrage Fund - Regular Plan16599001.87190.95
HDFC Arbitrage Fund - Wholesale Plan16599001.87190.95
ICICI Prudential Equity - Arbitrage Fund15367001.08176.78

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 23Mar 22Mar 21Mar 20Mar 19
FaceValue1.001.001.001.001.00
Basic EPS (Rs.)32.9045.1991.0548.3240.36
Diluted EPS (Rs.)32.9045.1991.0548.3240.36
Cash EPS (Rs.)54.3464.94109.9965.0551.71
Book Value[Excl.RevalReserv]/Share (Rs.)458.30419.42374.28286.92237.11
Book Value[Incl.RevalReserv]/Share (Rs.)458.30419.42374.28286.92237.11
Revenue From Operations / Share (Rs.)424.23400.33422.85394.24333.91
PBDIT / Share (Rs.)68.4380.3497.5386.3070.10
PBIT / Share (Rs.)47.1961.1179.5269.8058.70
PBT / Share (Rs.)44.7958.10126.2864.1452.72
Net Profit / Share (Rs.)33.1045.7191.9848.5540.31
NP After MI And SOA / Share (Rs.)32.9045.2091.0548.3240.36
PBDIT Margin (%)16.1320.0623.0621.8820.99
PBIT Margin (%)11.1215.2618.8017.7017.58
PBT Margin (%)10.5514.5129.8616.2715.78
Net Profit Margin (%)7.8011.4121.7512.3112.07
NP After MI And SOA Margin (%)7.7511.2921.5312.2512.08
Return on Networth / Equity (%)7.1810.7724.3216.8417.02
Return on Capital Employeed (%)9.7313.8920.0923.3123.82
Return On Assets (%)4.837.8015.759.788.93
Long Term Debt / Equity (X)0.020.010.010.000.01
Total Debt / Equity (X)0.180.090.220.320.48
Asset Turnover Ratio (%)0.430.400.600.570.62
Current Ratio (X)1.872.221.861.441.28
Quick Ratio (X)1.131.301.010.760.67
Inventory Turnover Ratio (X)1.240.931.151.171.31
Dividend Payout Ratio (NP) (%)22.799.954.396.206.19
Dividend Payout Ratio (CP) (%)13.856.983.664.624.83
Earning Retention Ratio (%)77.2190.0595.6193.8093.81
Cash Earning Retention Ratio (%)86.1593.0296.3495.3895.17
Interest Coverage Ratio (X)28.5496.7776.7116.5715.64
Interest Coverage Ratio (Post Tax) (X)14.8058.7035.5610.4110.33
Enterprise Value (Cr.)29138.9437374.6151145.9626780.8950849.31
EV / Net Operating Revenue (X)1.171.592.061.162.60
EV / EBITDA (X)7.277.948.955.3012.38
MarketCap / Net Operating Revenue (X)1.221.672.081.052.35
Retention Ratios (%)77.2090.0495.6093.7993.80
Price / BV (X)1.131.592.361.443.32
Price / Net Operating Revenue (X)1.221.672.081.052.35
EarningsYield0.060.060.100.110.05

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value: 818.97

The stock is overvalued by 24.66% compared to the current price ₹1087

Calculation basis:

  • Fair value = (P/E Ratio * (Return on Equity / 100) * Book Value) * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 18.75%, which is a positive sign.
  2. The company has higher reserves (13,369.00 cr) compared to borrowings (4,680.31 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (16.31 cr) and profit (14.85 cr) over the years.
  1. The stock has a high average Working Capital Days of 136.75, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 232.92, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Aurobindo Pharma Ltd:
    1. Net Profit Margin: 7.80%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 9.73% (Industry Average ROCE: 23.06%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 7.18% (Industry Average ROE: 42.79%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 14.80
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 1.13
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. ✓ Stock P/E: 22.7 (Industry average Stock P/E: 29.72)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. ✓ Total Debt / Equity: 0.18
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating: ★★★★︎☆

About the Company

Aurobindo Pharma Ltd. is a Public Limited Listed company incorporated on 26/12/1986 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L24239TG1986PLC015190 and registration number is 015190. Currently Company is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 11287.14 Cr. and Equity Capital is Rs. 58.59 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
PharmaceuticalsPlot No.2, Maitri Vihar, Hyderabad Telangana 500038info@aurobindo.com
http://www.aurobindo.com
Management
NamePosition Held
Mr. K RagunathanNon Exe.Chairman&Ind.Director
Mr. K Nithyananda ReddyVice Chairman & Mng.Director
Dr. M SivakumaranWhole Time Director
Mr. M Madan Mohan ReddyWhole Time Director
Mr. P V Ramprasad ReddyNon Executive Director
Mrs. Savita MahajanIndependent Director
Mr. Girish P VanvariIndependent Director
Dr.(Mrs.) Avnit Bimal SinghIndependent Director
Mr. Santanu MukherjeeIndependent Director

Aurobindo Pharma Ltd. Share Price Update

Share PriceValue
Today₹1,087.10
Previous Day₹1,114.90

FAQ

What is the latest fair value of Aurobindo Pharma Ltd?

The latest fair value of Aurobindo Pharma Ltd is 818.97.

What is the Market Cap of Aurobindo Pharma Ltd?

The Market Cap of Aurobindo Pharma Ltd is 63,694 Cr..

What is the current Stock Price of Aurobindo Pharma Ltd as on 21 April 2024?

The current stock price of Aurobindo Pharma Ltd as on 21 April 2024 is 1,087.

What is the High / Low of Aurobindo Pharma Ltd stocks in FY 2024?

In FY 2024, the High / Low of Aurobindo Pharma Ltd stocks is ₹1,177/581.

What is the Stock P/E of Aurobindo Pharma Ltd?

The Stock P/E of Aurobindo Pharma Ltd is 22.7.

What is the Book Value of Aurobindo Pharma Ltd?

The Book Value of Aurobindo Pharma Ltd is 481.

What is the Dividend Yield of Aurobindo Pharma Ltd?

The Dividend Yield of Aurobindo Pharma Ltd is 0.41 %.

What is the ROCE of Aurobindo Pharma Ltd?

The ROCE of Aurobindo Pharma Ltd is 9.20 %.

What is the ROE of Aurobindo Pharma Ltd?

The ROE of Aurobindo Pharma Ltd is 7.47 %.

What is the Face Value of Aurobindo Pharma Ltd?

The Face Value of Aurobindo Pharma Ltd is 1.00.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Aurobindo Pharma Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE